Brief: Esperion Therapeutics Q4 Basic EPS USD -0.5
27/02/2024 11:00
Feb 27 (Reuters) - Esperion Therapeutics Q4 product sales USD 20.76 million. * Q4 operating expenses USD 74.617 million * Q4 operating income USD -42.367 million * Q4 net income USD -56.344 million
Recent news on Esperion Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
U.S. RESEARCH ROUNDUP- Applied Materials, Axsome Therapeutics, Onsemi